Market Overview

UPDATE: Morgan Stanley Reiterates Overweight Rating, Raises PT on ResMed

Related RMD
Leader In The 'Growing' Sleep-Disordered Breathing Market Might Be Worth An Investment
Morning Market Losers
ResMed (RMD) Prepares for Q4 Earnings: What to Expect? - Analyst Blog (Zacks)

In a report published Wednesday, Morgan Stanley reiterated its Overweight rating on ResMed (NYSE: RMD), and slightly raised its price target from $32.95 to $33.37.

Morgan Stanley noted, “While recovery in US device growth was observed, ROW device growth looked likely to continue deceleration from double-digit growth in FY11 to the low-single-digit growth reported in Q212 – the positive surprise of +7.0% in Q312 was impressive against the trend of ASP pressure in France and changes to PSG payment in Germany, and the stock is now priced for the positive level to continue.”

ResMed closed on Tuesday at $31.56.

Latest Ratings for RMD

Jun 2015BarclaysInitiates Coverage onEqual-weight
Apr 2015Goldman SachsDowngradesBuyNeutral
Apr 2015MacquarieDowngradesOutperformNeutral

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (RMD)

Get Benzinga's Newsletters